item management s discussion and analysis of results of operations and of financial conditions general for more than years  c 
r 
bard  inc has committed its resources to creating innovative solutions to meet the needs of both health care providers and their patients 
the company is a global leader in the development  manufacture and supply of products and services to the health care industry 
bard addresses the health care opportunity through disease state management an approach that expands the focus from products and technologies to the underlying clinical condition  thereby positioning the company as an indispensable partner to the deliverers of health care 
bard is committed to developing leadership franchises within these disease states and using these strategic positions to leverage the company s growth 
summary results bard reported net sales of  million  up over net sales of  million 
holding currency rates constant  bard would have recorded an increase in total net sales over the prior year period 
the company demonstrated growth in each of its four product groups vascular  urology  oncology and surgery 
bard reported net income of million or of diluted earnings per share in compared with net income of million or of diluted earnings per share in both years earnings include one time items 
without these one time items  diluted earnings per share were in and in  an increase 
net of one time items  bard s margin of net income to net sales improved to from in results of operations vs 
net sales for totaled  million 
bard reported total net sales for of  million  a increase over ongoing net product sales in price reductions and the impact of a stronger dollar had the effect of reducing net sales by and  respectively 
excluding negative currency effects  total net sales would have increased in and in due to these negative currency effects  certain comparisons between and  where indicated  are made holding currency rates constant 
sales of vascular products increased in to million 
on a constant currency basis  these sales increased over the prior year 
the electrophysiology and peripheral technology franchises continued to show strong worldwide growth 
urology product group sales increased in to million and increased on a constant currency basis over the prior year 
both the infection control foley catheter and brachytheraphy products demonstrated solid sales growth 
sales of oncology products increased in to million despite the impact of the dialysis catheter recall 
adjusting for the currency impact  these product sales would have increased over the prior year 
endocinch tm endoscopic suturing system  a device used to treat gastroesophageal reflux disease gerd and bronchoscopy products were introduced this year 
gastroenterological products showed particularly strong growth internationally 
ii sales of surgery products grew in to million  paced by the mesh product lines  used primarily in hernia repair 
on a constant currency basis  these sales increased over the prior year 
other ongoing product sales grew in to million and increased on a constant currency basis over the prior year 
this product group includes irrigation  wound drainage and certain oem products 
net sales by product group for the last three years in thousands are vascular urology oncology surgery other ongoing products total ongoing products divested products net sales sales in the u 
s 
rose to million and represented of total net sales 
surgery products provided the best growth domestically 
sales outside the us increased to million and represented of total net sales 
oncology products demonstrated the best growth internationally 
for the year  excluding negative currency effects  net sales outside the us would have increased 
bard markets its products through direct selling organizations and selected distributors throughout the world 
the geographic breakdown  in percent  of net sales for each of the last three years is presented below united states europe japan rest of world total net sales cost of goods sold as a percent of net sales increased to in from in pricing pressures  the impact of currency  product recalls and lower margin oem business all contributed to this increase 
as a percent of sales  marketing  selling and administrative expense was  essentially flat as compared with the prior year figure of 
research and development expense remained consistent with the prior year at million and was complemented by million of spending for acquired technologies 
interest expense was million in  also consistent with the prior year 
ii please refer to note  other income expense  net  of the notes to consolidated financial statements for a summary of items in this category for the last three years 
in  the company announced that it would not exercise its option to acquire the remaining capital stock of endologix  inc  a california based company that had developed an endoluminal graft elg used for the minimally invasive treatment of abdominal aortic aneurysms 
as a result  the company recorded a pretax charge of million per share after tax for the write off of the endologix option and related assets and liabilities 
the company recorded one time gains in  and related to the series of dispositions of its cardiology product lines 
in the first quarter of  the company settled all remaining open issues related to these dispositions and recorded a gain of million per share after tax 
please refer to note  acquisitions and dispositions  of the notes to consolidated financial statements for additional disclosure 
the effective tax rate was in and in net income in  bard reported net income of million or diluted earnings per share of 
foreign exchange and the company s dialysis catheter recall negatively impacted results by approximately and per share  respectively 
the company recorded several one time items during excluding the after tax charge relating to the company s decision not to exercise the endologix option per share after tax  and the net after tax gain associated with other one time items  primarily asset dispositions and legal settlements per share after tax  diluted earnings per share was 
in  bard reported net income of million or diluted earnings per share of 
excluding the impact of the after tax gain on the sale of the cardiopulmonary business of per share and the after tax loss associated with the fourth quarter write down of impaired assets of per share  diluted earnings per share was 
in  bard reported net income of million or diluted earnings per share of 
excluding the impact of the after tax gain on the sale of the cardiology businesses of per share  the net after tax loss from one time items of per share and the after tax loss from year costs of per share  diluted earnings per share was 
results of operations vs 
net sales for totaled  million  which represented a increase over the prior year net sales of ongoing products of million 
price reductions and the impact of a stronger dollar had the effect of reducing reported net sales by and  respectively 
sales of vascular products rose in peripheral technology and electrophysiology devices showed strong worldwide growth 
ii urology product sales grew in basic drainage products experienced double digit growth  fueled by outstanding sales of infection control catheters 
sales of oncology products increased in specialty access devices showed good growth particularly in international markets 
sales of surgery products grew in  propelled by high worldwide growth of mesh products  used primarily for hernia repair 
net sales in the us of ongoing products rose to million 
the oncology and surgery products provided the best growth 
net sales of ongoing products outside the us increased to million with growth demonstrated by vascular and oncology products 
cost of goods sold as a percent of net sales declined from in to in this improvement was due to the company s manufacturing restructuring programs and the divestitures of the lower margin cardiology businesses 
marketing  selling and administrative expense declined in as a percent of net sales  these expenses declined to from in this reduction was attributed to the cardiology divestitures and improved efficiency in the company s sales and administration efforts 
reported research and development expense declined in due to the impact of the cardiology divestiture 
interest expense declined in due to lower average debt levels and improved operating cash flow 
other income expense  net  in included a pretax charge of million for the write down of impaired assets 
the company recorded one time gains in both and related to the dispositions of its cardiology businesses 
a pretax gain of million was recorded in the fourth quarter of and a pretax gain of million was recorded in the fourth quarter of please refer to note  acquisitions and dispositions  of the notes to consolidated financial statements for additional disclosure 
the effective tax rate was in and in the effective tax rate was impacted by the disposition of the cardiology business  which was taxed at approximately a rate 
net income in  net income was million or diluted earnings per share of 
excluding the impact of the after tax gain on the sale of the cardiopulmonary business of per share and the after tax loss from the fourth quarter write down of impaired assets of per share  diluted earnings per share was 
ii financial condition and liquidity bard s financial condition remains strong 
total debt was million at december   down from million at december  this decrease was the result of improved operating cash flow and the repayment of certain year end contingent borrowings 
total debt to total capitalization was at december   compared to at december   while net debt  or debt less cash and short term investments  to total capitalization was at december   compared to at december  shareholders investment was impacted in by the repurchase of million of common stock 
in  the company replaced its maturing million committed credit facility with a million five year committed credit facility that matures in may and a million day committed credit facility that matures in may these facilities support an actively used commercial paper program 
these facilities carry variable market rates of interest and require annual commitment fees 
at december   there were no borrowings under these facilities 
bard maintains uncommitted credit lines with banks for short term cash needs and these lines were used as needed during the last three years 
at december   the unused uncommitted lines of credit totaled million 
cash provided from operations continued to be the company s primary source of funds to finance operating needs  capital expenditures and dividend payments 
the company believes it could borrow adequate funds at competitive terms and rates  should it be necessary 
this overall financial strength gives bard sufficient financing flexibility 
total cash outlays made for the purchase of businesses  patents  trademarks  purchase rights  and other related items were approximately million in  million in and million in the majority of these investments were for intangible assets  reflecting the premium over book value for these purchases 
these cash outlays were financed with cash from operations and additional debt 
periodically  the company purchases its common stock in the open market to provide shares for issuance under various employee stock plans 
in connection with the announced sale of the cardiology businesses  the board of directors in july of authorized the purchase from time to time of up to million shares of common stock 
total shares purchased were  in   in  and  in foreign currency risk the company periodically enters into foreign exchange contracts and options to reduce its exposure to fluctuations in currency values 
contracts have been exclusively for the forward purchase of  and options in  currencies in which the company has known or anticipated sales or payments 
monetary assets of the company held in foreign currencies have relatively short maturities and are denominated in currencies that have not experienced wide  short term fluctuations in their equivalent us dollar values 
please refer to note  short term borrowings and long term debt  of the notes to consolidated financial statements for details of the company s foreign exchange contracts 
ii on january   the eleven original member countries of the european union began the transition to a common currency  the euro 
these participating countries expect the euro transition to be completed by july the company continues to evaluate potential euro related issues including pricing marketing strategy  conversion of computer systems  existing contracts and currency risk in the participating countries 
at the present time  management does not believe the euro conversion will have a materially adverse impact on our business 
restructuring in january  the company announced a series of strategic initiatives aimed at providing greater operating efficiencies  enhancing future funding of research and development and accelerating long term revenue growth 
these initiatives include the consolidation of all nonmanufacturing us operations into a single location in central new jersey 
in addition  the company will begin a multiyear project to substantially reduce the number of manufacturing facilities worldwide 
finally  the company is exploring alternatives for the consolidation of international administrative functions 
the company expects that the new jersey consolidation and the manufacturing restructuring will require up to three years to complete and will require a net cash investment of between and million for facilities  software and related infrastructure including personnel costs 
the majority of these investments will occur in and the company anticipates both one time charges and incremental operating expenses of approximately million or per share after tax in these costs would be associated with the first phase of the company s manufacturing consolidation project 
cautionary statement regarding forward looking information certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally may contain forward looking statements as defined in the private securities litigation reform act of you can identify these statements by the fact that they do not relate strictly to historic or current facts 
they use words such as anticipate  estimate  expect  project  intend  plan  believe and other words and terms of similar meaning in connection with any discussion of future operating or financial performance 
in particular  these include statements relating to future actions  prospective products or product approvals  future performance or results of current and anticipated products  sales efforts  expenses  the outcome of contingencies  such as legal proceedings  and financial results 
because actual results are affected by risks and uncertainties  the company cautions investors that actual results may differ materially from those expressed or implied 
it is not possible to predict or identify all such risks and uncertainties  but factors that could cause the actual results to differ materially from expected and historical results include  but are not limited to health care industry consolidation resulting in customer demands for price concessions and contracts that are more complex and have longer terms  competitive factors  including competitors attempts to gain market share through aggressive marketing programs  the development of new products or technologies by competitors and technological obsolescence  reduction in medical procedures performed in a cost conscious environment  the lengthy approval time by the fda or other government ii authorities to clear medical devices for commercial release  unanticipated product failures  legislative or administrative reforms to the us medicare and medicaid systems or other us or us reimbursement systems in a manner that would significantly reduce reimbursements for procedures using the company s medical devices  the acquisition of key patents by competitors that would have the effect of excluding the company from new market segments  the uncertainty of whether increased research and development expenditures will result in increased sales  unpredictability of existing and future litigation including litigation regarding product liability such as claims of alleged personal injuries as a result of exposure to natural rubber latex gloves distributed by the company as well as other product liability matters  and intellectual property matters and disputes on agreements which arise in the ordinary course of business  government actions or investigations affecting the industry in general or the company in particular  future difficulties obtaining product liability insurance on reasonable terms  efficacy or safety concerns with respect to marketed products  whether scientifically justified or not  that may lead to product recalls  withdrawals or declining sales  uncertainty related to tax appeals and litigation  future difficulties obtaining necessary components used in the company s products and or price increases from the company s suppliers of critical components  economic factors that the company has no control over  including changes in inflation  foreign currency exchange rates and interest rates  other factors that the company has no control over  including earthquakes  floods  fires and explosions  risks associated with maintaining and expanding international operations  and the risk that the company may not achieve manufacturing or administrative efficiencies as a result of the company s restructuring  the integration of acquired businesses or divestitures 
the company assumes no obligation to update forward looking statements as circumstances change 
you are advised  however  to consult any further disclosures we make on related subjects in our q  k and k reports 
ii 
